Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReBeL study in relapsed follicular lymphoma
NL-OMON22769Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, rituximab and bendamustine in follicular lymphoma (FL) (3 arms), sponsored by HOVON. Started Sep 2011; status: active, not recruiting.
02
Drugs
lenalidomiderituximabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON22769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22769.